logo
Plus   Neg
Share
Email

Alexion Pharma Agrees To Settle Charges Of FCPA Violations

The SEC announced that Alexion Pharmaceuticals Inc. (ALXN) has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act. SEC found that two Alexion subsidiaries made payments to foreign government officials to secure favorable treatment for the company's primary drug, Soliris.

"Alexion's internal accounting controls failed to detect and prevent payments to foreign government officials by its subsidiaries," said Melissa Hodgman, an Associate Director in the SEC's Division of Enforcement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk, chief executive of electric car maker Tesla, said its own battery cells, which are under development now, will not reach high-volume production until 2022. This delay can affect the Cybertruck, Semi, and Roadster programs. He also said the company intends to increase battery cell purchases from partners Panasonic, LG & CATL, and possibly other partners. U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test.
Follow RTT